The influence of genetic features on the psychological status of patients who suffered from a myocardial infarction (literature review)


DOI: https://dx.doi.org/10.18565/therapy.2021.9.104-112

Golovenkin S.Е., Nikulina S.Yu., Bubnova М.G., Orlova Yu.V., Maksimov V.N.

1) Krasnoyarsk State Medical University named after professor V.F. Voino-Yasenetsky of the Ministry of Healthcare of Russia; 2) National Medical Research Center of Therapy and Preventive Medicine of the Ministry of Healthcare of Russia, Moscow; 3) Research Institute of Therapy and Preventive Medicine – a branch of Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk
Abstract. Cardiac rehabilitation and secondary prevention of patients with acute myocardial infarction (MI) is an essential component in solving the common task of reducing mortality from cardiovascular causes. Unfortunately, not all patients after acute coronary events undergo a course of cardiac rehabilitation and then follow secondary prevention measures. An important place among the reasons for low compliance take the presence of anxiety and depression in this category of patients. The results of studies dedicated to the relationship between genetic peculiarities and psychological status of MI patients are discussed in the article. The role of a number of gene polymorphisms in the occurrence of anxiety and depression in such kind of patients is considered. The influence of age, comorbidity, duration of stress exposure and other factors influencing the psychological status of patients was revealed. An important section of the review is the discussion concerning candidate genes that can influence the interaction between MI and depression and may represent by themselves potential targets for therapeutic intervention.
Keywords: allele, depression, anxiety, myocardial infarction, secondary prevention, single nucleotide polymorphism, genetics, rehabilitation
Read entire article

Literature


  1. Naghavi M., Wang H., Lozano R. et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117–71. doi: 10.1016/S0140-6736(14)61682-2.

  2. Бойцов С.А., Погосова Н.В., Бубнова М.Г. с соавт. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018; 6: 7–122. [Boitsov S.A., Pogosova N.V., Bubnova M.G. et al. Cardiovascular prevention 2017. National guidelines. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018; 6: 7–122 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2018-6-7-122.

  3. Аронов Д.М., Бубнова М.Г., Барбараш О.Л. с соавт. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы: реабилитация и вторичная профилактика. Российские клинические рекомендации. CardioСоматика. 2014; S1: 5–41. [Aronov D.M., Bubnova M.G., Barbarash O.L. et al. Acute myocardial infarction with ST segment elevation electrocardiograms: rehabilitation and secondary prevention. Russian clinical guidelines. CardioSomatica. 2014; S1: 5–41 (In Russ.)].

  4. Демографический ежегодник России. 2015: Статистический сборник Росстата. M. 2015; 263 c. [Demographic yearbook of Russia. 2015: Statistical collection of Rosstat. Moscow. 2015; 263 pp. (In Russ.)].

  5. Аронов Д.М. История развития кардиореабилитации в России. Кардиология. 2018; S11: 14–21. [Aronov D.M. History of cardiac rehabilitation in Russia. Kardiologiya = Cardiology. 2018; S11: 14–21 (In Russ.)]. https://dx.doi.org/10.18087/cardio.2604.

  6. Аронов Д.М., Бубнова М.Г. Проблемы внедрения новой системы кардиореабилитации в России. Российский кардиологический журнал. 2013; 4: 14–22. [Aronov D.M., Bubnova M.G. Challenges of the implementation of a new cardiac rehabilitation system in Russia. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2013; 4: 14–22 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2013-4-14-22.

  7. O'Gara P.T., Kushner F.G., Ascheim D.D. еt al. ACCF/AHA guidelines for the management of ST-elevation myocardial infarction. A report of the American College of Cardiology Foundation/American Heart Association. Task force on practice guidelines. J Am Coll Cardiol. 2011; 61(4): e78–e140. doi: 10.1016/j.jacc.2012.11.019.

  8. Steg G., James S.K., Atar D. et al. ESC Guidelines for the management of acute myocardial Infarction in patients presenting with ST-segment elevation. Task force on management of elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012; 33(20): 2569–619. doi: 10.1093/eurheartj/ehs215.

  9. Levine G.N., Bates E., Blankenship J.C. et al. ACC/AHA/SCAI 2011 guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association. Task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58(24): e44–122. doi: 10.1016/j.jacc.2011.08.007.

  10. Wijns W., Kolh P., Danchin N. et al. Guidelines on myocardial revascularization. ESC/EACTS guidelines. Eur Heart J. 2010; 31(20): 2501–55. doi: 10.1093/eurheartj/ehq277.

  11. Taylor R.S., Brown A., Ebrahim S. et al. Exercise-based rehabilitation for patients with coronary heart disease: review and meta-analysis of randomized controlled trials. Am J Med. 2004; 116(10): 682–92. doi: 10.1016/j.amjmed.2004.01.009.

  12. de Vries H., Kemps H.M.C., van Engen-Verheul M.M. et al. Cardiac rehabilitation and survival in a large representative community cohort of Dutch patients. Eur Heart J. 2015; 36(24): 1519–28. doi: 10.1093/eurheartj/ehv111.

  13. De Schutter A., Kachur S., Lavie C.J. et al. Cardiac rehabilitation fitness changes and subsequent survival. Eur Heart J Qual Care Clin Outcomes. 2018; 4(3): 173–79. doi: 10.1093/ehjqcco/qcy018.

  14. Doimo S., Fabris E., Piepoli M. et al. Impact of ambulatory cardiac rehabilitation on cardiovascular outcomes: A long-term follow-up study. Eur Heart J. 2019; 40(8): 678–85. doi: 10.1093/eurheartj/ehy417.

  15. Аронов Д.М. Кардиореабилитация больных ИБС: рецепт для России. Лечащий врач. 2007; 3: 22–26. [Aronov D.M. Cardiorehabilitation of patients with coronary heart disease: a recipe for Russia. Lechashchiy vrach = Attending Physician. 2007; 3: 22–26 (In Russ.)].

  16. Grace S., Chessex C., Arthur H. et al. Systematizing inpatient referral to cardiac rehabilitation 2010: Canadian Association of Cardiac Rehabilitation and Canadian Cardiovascular Society joint position paper. J Cardiopulm Rehabil Prev. 2011; 31(3): E1–8. doi: 10.1097/HCR.0b013e31829721f.

  17. Ades P.A., Keteyian S.J., Wright J.S. et al. Increasing cardiac rehabilitation participation from 20% to 70%: A road map from the Million Hearts Cardiac Rehabilitation Collaborative. Mayo Clin Proc. 2017; 92(2): 234–42. doi: 10.1016./j.mayocp.2016.10.014.

  18. Turk-Adawi K.I., Oldridge N.B., Tarima S.S. et al. Cardiac rehabilitation enrollment among referred patients. Рatient and organizational factors. J Cardiopulm Rehabil Prev. 2014; 34(2): 114–22. doi: 10.1097/HCR.0000000000000017.

  19. Endo N., Goto A., Suzuki T. et al. Factors associated with enrollment and adherence in outpatient cardiac rehabilitation in Japan. J Cardiopulm Rehabil Prev. 2015; 35(3): 186–92. doi: 10.1097/HCR.0000000000000103.

  20. Бубнова М.Г. Актуальные проблемы участия и обучения кардиологических пациентов в программах кардиореабилитации и вторичной профилактики. Кардиоваскулярная терапия и профилактика. 2020; 6: 2649. [Bubnova M.G. Relevant problems of participation and education of patients in cardiac rehabilitation and secondary prevention programs. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2020; 6: 2649 (In Russ.)]. https://doi.org/10.15829/1728-8800-2020-2649.

  21. Аронов Д.М., Бубнова М.Г., Драпкина О.М. Немедикаментозная терапия больных с сердечно-сосудистыми заболеваниями в программах кардиореабилитации. Профилактическая медицина. 2020; 6–2: 57–64. [Aronov D.M., Bubnova M.G., Drapkina O.M. Non-pharmacological therapy of patients with cardiovascular diseases in cardiac rehabilitation programs. Profilakticheskaya meditsina = The Russian Journal of Preventive Medicine. 2020; 6–2: 57–64 (In Russ.)]. https://doi.org/10.17116/profmed20202306257.

  22. Menezes A.R., Lavie C.J., Milani R.V. et al. Cardiac rehabilitation in the United States. Prog Cardiovasc Dis. 2014; 56(5): 522–29. doi: 10.1016/j.pcad.2013.09.018.

  23. Bustamante M.J., Valentino G., Kramer V. et al. Patient adherence to a cardiovascular rehabilitation program: What factors are involved? Int J Clin Med. 2015; 6(9): 605–14. doi: 10.4236/ijcm.2015.69081.

  24. Soroush A., Heydarpour B., Komasi S. et al. Barriers for the referral to outpatient cardiac rehabilitation: A predictive model including actual and perceived risk factors and perceived control. Ann Card Anaesth. 2018; 21(3): 249–54. doi.10.4103/aca.ACA_87_17.

  25. Cortes-Beringola A., Fitzsimons D., Pelliccia A. et al. Planning secondary prevention: Room for improvement. Eur J Prev Cardiol. 2017; 24(3S): 22–28. doi: 10.1177/2047487317704954.

  26. Fumeron F., Betoulle D., Nicaud V. et al. Serotonin transporter gene polymorphism and myocardial infarction: Etude Cas-Temoins de l’Infarctus du Myocarde (ECTIM). Circulation. 2002; 105(25): 2943–45. doi: 10.1161/01.cir.0000022603.92986.99.

  27. Nakatani D., Sato H., Sakata Y. et al. Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. Am Heart J. 2005; 150(4): 652–58. doi: 10.1016/j.ahj.2005.03.062.

  28. Голимбет В.Е., Волель Б.А., Должиков А.В., Исаева М.И. Исследование роли полиморфизма 5-HTTLPR гена переносчика серотонина в развитии депрессии при ишемической болезни сердца. Журнал неврологии и психиатрии им. C.C. Корсакова. 2012; 8: 63–69. [Golimbet V.E., Volel’ B.A., Dolzhikov A.V., Isaeva M.I. The role of the 5-HTTLPR polymorphism of the serotonin transporter gene in the development of depression in patients with coronary heart disease. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = Journal of Neurology and Psychiatry named after S.S. Korsakov. 2012; 8: 63–69 (In Russ.)].

  29. Zhang L.J., Zeng X.T., Zhao M.J. et al. The important effect of 5-HTTLPR polymorphism on the risk of depression in patients with coronary heart disease: a meta-analysis. BMC Cardiovasc Disord. 2020; 20(1):141. doi: 10.1186/s12872-020-01424-1.

  30. Meyer T., Rothe I., Staab J. et al. SPIRR-CAD Investigators. Length polymorphisms in the angiotensin I-converting enzyme gene and the serotonin-transporter-linked polymorphic region constitute a risk haplotype for depression in patients with coronary artery disease. Biochem Genet. 2020; 58(4): 631–48. doi: 10.1007/s10528-020-09967-w.

  31. Liu Y.Q., Su G.B., Duan C.H. et al. Brain-derived neurotrophic factor gene polymorphisms are associated with coronary artery disease-related depression and antidepressant response. Mol Med Rep. 2014; 10(6): 3247–53. doi: 10.3892/mmr.2014.2638.

  32. Amadio P., Colombo G.I., Tarantino E. et al. BDNFVal66met polymorphism: a potential bridge between depression and thrombosis. Eur Heart J. 2017; 38(18): 1426–35. doi: 10.1093/eurheartj/ehv655.

  33. Kang H.J., Bae K.Y., Kim S.W. et al. BDNF val66met polymorphism and depressive disorders in patients with acute coronary syndrome. J Affect Disord. 2016; 194: 1–8. doi: 10.1016/j.jad.2016.01.033.

  34. Westermair A.L., Munz M., Schaich A. et al. Association of genetic variation at AQP4 locus with vascular depression. Biomolecules. 2018; 8(4): 164. doi: 10.3390/biom8040164.

  35. Zhang X., Huo Q., Sun W. et al. Rs2910164 in microRNA‑146a confers an elevated risk of depression in patients with coronary artery disease by modulating the expression of NOS1. Mol Med Rep. 2018; 18(1): 603–09. doi: 10.3892/mmr.2018.8929.

  36. Dai Z., Li Q., Yang G. et al. Using literature-based discovery to identify candidate genes for the interaction between myocardial infarction and depression. BMC Med Genet. 2019; 20(1): 104. doi: 10.1186/s12881-019-0841-8.

  37. Brandt J., Warnke K., Jorgens S. et al. Association of FKBP5 genotype with depressive symptoms in patients with coronary heart disease: A prospective study. J Neural Transm (Vienna). 2020; 127(12): 1651–62. doi: 10.1007/s00702-020-02243-6.

  38. Khandaker G.M., Zuber V., Rees J.M.B. et al. Shared mechanisms between coronary heart disease and depression: Findings from a large UK general population-based cohort. Mol Psychiatry. 2020; 25(7): 1477–86. doi: 10.1038/s41380-019-0395-3. Epub 2019 Mar 19. Erratum in: Mol Psychiatry. 2020 Aug 17.

  39. Han W., Wei Z., Dang R. et al. Angiotensin-II and angiotensin-(1-7) imbalance affects comorbidity of depression and coronary heart disease. Peptides. 2020; 131: 170353. doi: 10.1016/j.peptides.2020.170353.

  40. Han W., Zhang H., Gong X. et al. Association of SGK1 polymorphisms with susceptibility to coronary heart disease in Chinese Han patients with comorbid depression. Front Genet. 2019; 10: 921. doi: 10.3389/fgene.2019.00921.

  41. Purves K.L., Coleman J.R.I., Meier S.M. et al. A major role for common genetic variation in anxiety disorders. Mol Psychiatry. 2020; 25(12): 3292–303. doi: 10.1038/s41380-019-0559-1.

  42. Hagenaars S.P., Coleman J.R.I., Choi S.W. et al. Genetic comorbidity between major depression and cardio-metabolic traits, stratified by age at onset of major depression. Am J Med Genet B Neuropsychiatr Genet. 2020; 183(6): 309–30. doi: 10.1002/ajmg.b.32807.

  43. Akosile W., Voisey J., Lawford B. et al. The inflammasome NLRP12 is associated with both depression and coronary artery disease in Vietnam veterans. Psychiatry Res. 2018; 270: 775–79. doi: 10.1016/j.psychres.2018.10.051.

  44. Wang H., Ba Y., Han W. et al. Association of heat shock protein polymorphisms with patient susceptibility to coronary artery disease comorbid depression and anxiety in a Chinese population. Peer J. 2021; 9: e11636. doi: 10.7717/peerj.11636.

  45. Otte C., Wust S., Zhao S. et al. Glucocorticoid receptor gene and depression in patients with coronary heart disease: The Heart and Soul Study-2009 Curt Richter Award Winner. Psychoneuroendocrinology. 2009; 34(10): 1574–81. doi: 10.1016/j.psyneuen.2009.08.016.

  46. Alghamdi J., Matou-Nasri S., Alghamdi F. et al. Risk of neuropsychiatric adverse effects of lipid-lowering drugs: A Mendelian randomization study. Int J Neuropsychopharmacol. 2018; 21(12): 1067–75. doi: 10.1093/ijnp/pyy060.


About the Autors

Sergey E. Golovenkin, PhD, associate professor of the Department of faculty therapy with the course of FPE, Krasnoyarsk State Medical University named after professor V.F. Voino-Yasenetsky of the Ministry of Healthcare of Russia. Address: 660014, Krasnoyarsk, 12 Instrumentalnaya Str. Tel.: +7 (904) 890-35-42. E-mail: gse2008@mail.ru. ORCID: 0000-0003-0320-9312
Svetlana Yu. Nikulina, MD, professor, head of the Department of faculty therapy with a course of FPE, Krasnoyarsk State Medical University named after professor V.F. Voino-Yasenetsky of the Ministry of Healthcare of Russia. Address: 660014, Krasnoyarsk, 12 Instrumentalnaya Str. Tel.: +7 (908) 212-53-79. E-mail: nicoulina@mail.ru. ORCID: 0000-0002-6968-7627
Marina G. Bubnova, MD, professor, head of the Department of rehabilitation and secondary prevention of cardiovascular diseases, National Medical Research Center of Therapy and Preventive Medicine of the Ministry of Healthcare of Russia. Address: 101990, Moscow, 10 Petroverigsky Lane. Tel.: +7 (903) 752-21-86. E-mail: mbubnova@gnicpm.ru. ORCID: 0000-0003-2250-5942
Yulia V. Orlova, clinical resident of the Department of faculty therapy with the course of FPE, Krasnoyarsk State Medical University named after professor V.F. Voino-Yasenetsky of the Ministry of Healthcare of Russia. Address: 660014, Krasnoyarsk, 12 Instrumentalnaya Str. E-mail: juliann303@yandex.ru
Vladimir N. Maksimov, MD, professor, head of the laboratory of molecular genetic studies of therapeutic pathology, Research Institute of Therapy and Preventive Medicine – a branch of Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences. Address: 630089, Novosibirsk, 175/1 Borisa Bogatkova Str. Tel.: +7 (913) 903-44-89. E-mail: medik11@mail.ru. ORCID: 0000-0002-7165-4496


Similar Articles

Back to Content

Бионика Медиа